During the past decade, RKU - Universitäts und Rehabilitationskliniken Ulm gGmbH conducted 6 clinical trials. In the 10-year time frame, 6 clinical trials started and 4 clinical trials were completed, i.e. on average, 66.7% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 3 clinical trials were completed. i.e. 150% of trials that started reached the finish line.

Out of the total clinical trials conducted in "RKU - Universitäts und Rehabilitationskliniken Ulm gGmbH" #1 sponsor was "Knopp Biosciences" with 2 trials, followed by "Allon Therapeutics" with 1 trials sponsored, "Boehringer Ingelheim" with 1 trials sponsored, "Britannia Pharmaceuticals Ltd." with 1 trials sponsored and "Mitsubishi Tanabe Pharma America Inc." with 1 trials sponsored. Other sponsors include -1 different institutions and companies that sponsored additional 9 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "RKU - Universitäts und Rehabilitationskliniken Ulm gGmbH" #1 collaborator was "Biogen" with 1 trials as a collaborator and "Muscular Dystrophy Association" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "RKU - Universitäts und Rehabilitationskliniken Ulm gGmbH" are "Amyotrophic Lateral Sclerosis" (2 trials), "ALS" (1 trials), "Advanced Parkinson Disease" (1 trials), "Brain Ischemia With Non-valvular Atrial Fibrillation" (1 trials) and "Carotid Artery Stenosis" (1 trials). Many other conditions were trialed in "RKU - Universitäts und Rehabilitationskliniken Ulm gGmbH" in a lesser frequency.

Most popular intervention types in "RKU - Universitäts und Rehabilitationskliniken Ulm gGmbH" are "Drug" (7 trials), "Combination Product" (1 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "Dexpramipexole" (2 trials), "ASA 100 mg" (1 trials), "Davunetide" (1 trials) and "Lecigon® based on European Medicines Agency (EMA) SmPC" (1 trials). Other intervention names were less common.

The vast majority of trials in "RKU - Universitäts und Rehabilitationskliniken Ulm gGmbH" are 10 trials for "All" genders.

Currently, there are NaN active trials in "RKU - Universitäts und Rehabilitationskliniken Ulm gGmbH". undefined are not yet recruiting, 1 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 6 completed trials in RKU - Universitäts und Rehabilitationskliniken Ulm gGmbH, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in RKU - Universitäts und Rehabilitationskliniken Ulm gGmbH, 1 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".

RKU - Universitäts und Rehabilitationskliniken Ulm gGmbH has several departments that took part in Clinical trials: "Universitäts- und Rehabilitationskliniken Ulm (RKU) - Neurologische Universitätsklinik" - 2 trials